Walmart Q2 Earnings: Smashes Expectations, Strong E-Commerce Growth and Raised Outlook

Walmart Inc (NYSE: WMT) reported 

Walmart Inc (NYSE:WMT) reported second-quarter FY24 sales growth of 5.7% year-on-year to $161.10 billion, beating the analyst consensus estimate of $160.27 billion.

Net sales from Walmart U.S. increased 5.4% Y/Y, Walmart International rose 13.3%, and Sam’s Club fell 0.3%.

Excluding fuel, Walmart’s U.S. Q2 comp sales grew 6.4%. eCommerce growth was 24%.

Global advertising business grew by over 35%.

The consolidated gross margin rate gained 50 basis points to 24% on lapping elevated markdowns and supply chain costs, partially offset by ongoing mix pressure in grocery and health & wellness.

The operating margin was 4.5%, and operating income for the quarter rose 6.7% to $7.3 billion.

Cash provided by operating activities for six months totaled $18.2 billion, with a free cash flow of $8.98 billion. The company held $13.88 billion in cash and equivalents as of July 31, 2023.

Adjusted EPS was $1.84, beating the consensus of $1.70. The return on investment for the quarter declined 100 basis points to 12.8%, down by 100bps.

Year-to-date, Walmart repurchased 8 million shares worth $1.2 billion with a remaining share repurchase authorization of $18.2 billion.

Adjusted EBITDA for Q2 was $10.3 billion with a 6.4% margin.

Outlook: Walmart sees a Q3 FY24 adjusted EPS of $1.45 – $1.50 (consensus $1.49). Q3 net sales growth of 3% in CC.

For FY24, the company raised FY24 adjusted EPS guidance from $6.10 – $6.20 to $6.36 – $6.46 versus an estimate of $6.27. It raised FY24 net sales growth outlook to 4% – 4.5% from 3.5% earlier.

Price Action: WMT shares are trading higher by 1.29% at $161.32 in premarket on the last check Thursday.

Total
0
Shares
Related Posts
Read More

Impel Pharmaceuticals Earlier Announced Streamlining Plan, Including 16% Workforce Reduction, Largely In The R&D Functions, The Company Plans To Reprioritize Spending On Trudhesa (Dihydroergotamine Mesylate) Nasal Spray For Migraine

The plan will halt research and development efforts on INP105 (olanzapine) to address acute agitation and aggression in autism spectrum disorder.  Aligned with this, the Company also announced that Stephen

IMPL

Read More

Kingsway Financial Services’ Unit Entered Into A Purchase And Sale Agreement With BNSF Dayton To Sell Certain Real Property In Liberty County, Texas; Closing Purchase Price Consists Of $44.5M In Cash Plus Assumption Of Existing Loans Of ~$172.2M

On December 22, 2022, TRT Leaseco, LLC (“Kingsway Seller”), an indirect subsidiary of Kingsway Financial Services Inc. (the “Company”), entered into a Purchase and Sale Agreement (the

KFS